Combining Lesinurad With Allopurinol in Inadequate Responders

PHASE3CompletedINTERVENTIONAL
Enrollment

607

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions
Gout
Interventions
DRUG

Lesinurad

Tablets, 200 mg once daily (qd)

DRUG

Lesinurad

Tablets, 400 mg qd

DRUG

Placebo

Tablets, Placebo qd

DRUG

Allopurinol

Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)

DRUG

Allopurinol

Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)

DRUG

Allopurinol

Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)

Trial Locations (165)

10016

New York

13210

Syracuse

13760

Endwell

14221

Williamsville

15012

Belle Vernon

15025

Clairton

15090

Wexford

15206

Pittsburgh

15241

Upper Saint Clair

16602

Altoona

16635

Duncansville

18960

Sellersville

19046

Jenkintown

19446

Lansdale

20110

Manassas

23114

Midlothian

23233

Richmond

23235

Richmond

23320

Chesapeake

23435

Suffolk

23462

Virginia Beach

26505

Morgantown

27103

Winston-Salem

27405

Greensboro

27609

Raleigh

27612

Raleigh

28150

Shelby

28401

Wilmington

28463

Tabor City

29204

Columbia

29303

Spartanburg

29464

Mt. Pleasant

29588

Myrtle Beach

29732

Rock Hill

30013

Conyers

30060

Marietta

30097

Johns Creek

30265

Newnan

30308

Atlanta

30328

Atlanta

30909

Augusta

32114

Daytona Beach

32127

Port Orange

32174

Ormond Beach

32607

Gainesville

32960

Vero Beach

33027

Pembroke Pines

33029

Pembroke Pines

33125

Miami

33135

Miami

33143

Miami

33165

Miami

33186

Miami

33614

Tampa

33765

Clearwater

34102

Naples

34208

East Bradenton

34474

Ocala

34601

Brooksville

35126

Pinson

35209

Birmingham

35213

Birmingham

35242

Birmingham

35294

Birmingham

35611

Athens

36542

Gulf Shores

36604

Mobile

36608

Mobile

37027

Brentwood

37923

Knoxville

38119

Memphis

38305

Jackson

39202

Jackson

41701

Elizabethtown

42003

Paducah

43235

Columbus

43551

Perrysburg

44904

Willoughby Hills

45417

Dayton

46131

Franklin

46350

La Porte

47714

Evansville

48034

Southfield

48106

Ann Arbor

49009

Kalamazoo

49684

Traverse City

52403

Cedar Rapids

53226

Milwaukee

53566

Monroe

59808

Missoula

60031

Gurnee

60612

Chicago

63031

Florissant

63042

Hazelwood

63090

Washington

63117

St Louis

63128

St Louis

64114

Kansas City

65109

Jefferson City

66218

Shawnee

70006

Metairie

70535

Eunice

71203

Monroe

71457

Natchitoches

72204

Little Rock

72206

Little Rock

72211

Little Rock

73103

Oklahoma City

74104

Tulsa

75024

Plabo

75075

Plano

75218

Dallas

76135

Fort Worth

76708

Waco

76904

San Angelo

77004

Houston

77043

Houston

77058

Nassau Bay

77062

Houston

77098

Houston

77339

Kingwood

77474

Sealy

78209

San Antonio

78215

San Antonio

78229

San Antonio

78414

Corpus Christi

78756

Austin

79902

El Paso

80113

Englewood

80230

Denver

80907

Colorado Springs

80918

Colorado Springs

83404

Idaho Falls

83642

Meridian

83646

Meridian

84010

Bountiful

84088

West Jordan

84102

Salt Lake City

85050

Phoenix

85308

Glendale

85381

Peoria

85395

Goodyear

85704

Tucson

85723

Tuscon

87102

Albuquerque

89119

Las Vegas

89183

Las Vegas

90301

Inglewood

91204

Glendale

91723

Covina

92646

Huntington Beach

92868

Orange

93454

Santa Maria

93534

Lancaster

94578

San Leandro

95648

Lincoln

95825

Sacramento

96814

Honolulu

97520

Ashland

98366

Port Orchard

99204

Spokane

99208

Spokane

06460

Milford

06320

New London

01605

Worcester

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY

NCT01510158 - Combining Lesinurad With Allopurinol in Inadequate Responders | Biotech Hunter | Biotech Hunter